GlassScriptPhysician profile
Junemarie Williams
NPI 1225072622
$1,662.50
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $629 · 2023: $1,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,033.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,033.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $402.42 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $214.19 | 2022-2023 | Spravato |
| Alkermes, INC. | $179.39 | 2022-2023 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $165.77 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $140.77 | 2022-2023 | Rexulti, Nuedexta |
| Corium, LLC | $85.10 | 2023 | Azstarys |
| Lundbeck LLC | $81.32 | 2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $80.26 | 2023 | Trintellix |
| Axsome Therapeutics, INC. | $77.68 | 2023 | Auvelity, Sunosi |
| Neos Therapeutics, LP | $68.32 | 2022-2023 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $46.43 | 2023 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $35.16 | 2022-2023 | Austedo Xr |
| Almatica Pharma LLC | $33.76 | 2022-2023 | Loreev Xr |
| Sunovion Pharmaceuticals INC. | $32.06 | 2022 | |
| Indivior INC. | $19.87 | 2023 | Sublocade |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Junemarie Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.